Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1997-04-21
2004-06-08
Romeo, David S. (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S300000
Reexamination Certificate
active
06747138
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to Fas-mediated cellular functions and methods for the regulation of Fas-mediated cellular functions in a population of cells.
BACKGROUND OF THE INVENTION
Programmed cell death (PCD) is a physiologic process essential to the normal development and homeostatic maintenance of multicellular organisms (reviewed in Vaux et al. (1994) Cell 76:777-779 and Ellis et al. (1991)
Ann. Rev. Cell Biol
. 7:663-698). Apoptosis, often equated with PCD, refers to the morphologic alterations exhibited by “actively” dying cells which include cell shrinkage, membrane blebbing and chromatin condensation. (For a general review of apoptosis, see Tomei, L. D. and Cope, F. O.
Apoptosis: The Molecular Basis of Cell Death
(1991) Cold Spring Harbor Press, N.Y.; Tomei, L. D.; Cope, F. O.
Apoptosis II: The Molecular Basis of Apoptosis in Disease
(1994) Cold Spring Harbor Press, New York; Duvall and Wyllie (1986)
Immun. Today
7(4):115-119 and Cohen (1993)
Immunol. Today
14:126-130.) In contrast, necrosis, sometimes referred to as accidental cell death, is defined by the swelling and lysis of cells that are exposed to toxic stimuli.
Apoptosis has been linked to many biological processes, including embryogenesis, development of the immune system, elimination of virus-infected cells, and the maintenance of tissue homeostasis. Apoptosis also occurs as a result of human immunodeficiency virus (HIV) infection of CD4
+
T lymphocytes (T cells). Indeed, one of the major characteristics of AIDS is the gradual depletion of CD4
+
T lymphocytes during the development of the disease. Several mechanisms, including apoptosis, have been suggested to be responsible for the CD4 depletion. It is speculated that apoptotic mechanisms might be mediated either directly or by the virus replication as a consequence of the HIV envelope gene expression, or indirectly by priming uninfected cells to apoptosis when triggered by different agents.
The depletion of CD4
+
T cells results in the impairment of the cellular immune response. It has been reported that an inappropriate activation-induced T cell PCD causes the functional and numerical abnormalities of T
H
cells from HIV-infected patients, that leads to the near collapse of the patient's immune system. (Brunner, T. et al. (1995)
Nature
373:441-444; Dhein, J. et al. (1995)
Nature
373:438-441; and Ju, S-T. et al. (1995)
Nature
373:444-448).
Therefore, it is advantageous to block apoptosis and the ensuing depletion of T cells, especially in HIV infected individuals. Accordingly, a need exists to maintain T cell function and viability in HIV infected individuals and to provide systems to screen for new drugs that may assist in maintaining the cellular immune response. This invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
This invention provides a novel purified mammalian protein designated FADD having the ability to bind the cytoplasmic region or domain of the Fas receptor.
Also provided by this invention are nucleic acid molecules that encode the mammalian protein which binds the intracellular domain of Fas.
An antibody, such as a monoclonal antibody, with specific affinity for FADD is further provided by this invention.
Methods of using the proteins, nucleic acids and antibodies described above are further provided herein.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4754065 (1988-06-01), Levenson et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 5258454 (1993-11-01), Berg et al.
patent: 5674734 (1997-10-01), Leder et al.
patent: WO 93/25685 (1993-12-01), None
patent: WO 93/25694 (1993-12-01), None
patent: 9418317 (1994-08-01), None
patent: WO 94/21817 (1994-09-01), None
patent: WO 94/24297 (1994-10-01), None
patent: WO 94/25621 (1994-11-01), None
patent: WO 94/27583 (1994-12-01), None
patent: WO 96/01642 (1996-01-01), None
patent: WO 96/20721 (1996-07-01), None
patent: WO 96/36698 (1996-11-01), None
patent: WO 96/40713 (1996-12-01), None
patent: WO 97/18313 (1997-05-01), None
patent: WO 98/03648 (1998-01-01), None
Maekawa et al. FEBS Letters. vol. 337, pp. 200-206. Molecular cloning of a novel protein-tyrosine phosphatase containing a membrane-binding domain and GLGF repeats, Jan. 10, 1993.*
Marshall, et al. EMBO J. vol. 9(13): pp. 4391-4398, GENEBANKa101, Accession No. X55439, 1990.*
Allison et al., “The yin and yang of T cell costimulation”Science(1995) 270:932-933.
Barres et al., “Cell death and control of cell survival in the oligodendrocyte lineage” Cell (1992) 70:31-46.
Beidler et al., “The baculovirus p35 protein inhibits fas- and tumor necrosis factor-induced apoptosis”J. Biol. Chem.(1995) 270:16526-16528.
Blau et al., “Molecular medicine: Gene therapy—a novel form of drug delivery”N. Eng. J. Med.(1995) 333:1204-1207.
Bose et al., “Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals”Cell(1995) 82:405-414.
Boudreau et al., “Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix”Science(1995) 267:891-893.
Boulakia et al., “Bcl-2 and adenovirus E1B 19 kDa protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase”Oncogene(1996) 12:529-535.
Bump et al., “Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35”Science(1995) 269:1885-1888.
Casciola-Rosen et al., “Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death”J. Biol. Chem.(1994) 269:30757-30760.
Chinnaiyan et al., “FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis”J. Biol. Chem.(1996) 271:4961-4965.
Chinnaiyan et al., “Molecular ordering of the cell death pathway”J. Biol. Chem.(1996) 271:4573-4576.
Clem et al., “Prevention of apoptosis by a baculovirus gene during infection of insect cells”Science(1991) 254:1388-1390.
Clem et al., “Control of programmed cell death by the baculovirus genes p35 and iap”Mol.&Cell. Biol.(1994) 14:5212-5222.
Cleveland et al., “Contenders in FasL/TNF death signaling”Cell(1995) 81:479-482.
Correll et al., “Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells” Proc. Natl. Acad. Sci. USA (1989) 86:8912-8916.
Darmon et al., “Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B”Nature(1995) 377:446-448.
Dixit et al., “Tumor necrosis factor-&agr; induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin” J. Biol. Chem. (1990) 265:2973-2978.
Duan et al., “ICE-LAP3, a novel mammalian homologue of theCaenorhabditis eleganscell death protein CED-3 is activated during Fas- and tumor necrosis factor-induced apoptosis”J. Biol. Chem.(1996) 271:1621-1625.
Ellis et al., “Genetic control of programmed cell death in the nematodeC. elegans” Cell(1986) 44:817-829.
Faucheu et al., “A novel human protease similar to the interleukin-1&bgr; converting enzyme induces apoptosis in transfected cells”EMBO J.(1995) 14:1914-1922.
Fernandes-Alnemri et al., “CPP32, a novel human apoptotic protein with homology toCaenorhabditis eleganscell death protein Ced-3 and mammalian interleukin-1&bgr;-converting enzyme”J. Biol. Chem.(1994) 269:30761-30764.
Fernandes-Alnemri et al., “Mch2, a new member of the apoptotic Ced-3/Ice cysteine protease gene family”Cancer Res.(1995) 55:2737-2742.
Fernandes-Alnemri et al., “Mch3, a novel human apoptotic cysteine protease highly related to CPP32”Cancer Res.(1995) 55:6045-6052.
Finkel et al., “Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes”Nature Med.(1995) 1:129-134.
Fisher et al., “Dominant interfering Fas gene Mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome”Cell(1995) 81:935-946.
Gagliardini et al., “Prevention of vertebrate neuronal death by the crmA
Dixit Vishva M.
O'Rourke Karen
Regents of the University of Michigan
Romeo David S.
LandOfFree
Methods and compositions for regulating Fas-associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for regulating Fas-associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for regulating Fas-associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3355201